Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

Author:

Chao Joseph1,Fuchs Charles S.2,Shitara Kohei3,Tabernero Josep4,Muro Kei5,Van Cutsem Eric6,Bang Yung-Jue7,De Vita Ferdinando8,Landers Gregory9,Yen Chia-Jui10,Chau Ian11,Elme Anneli12,Lee Jeeyun13,Özgüroglu Mustafa14,Catenacci Daniel15,Yoon Harry H.16,Chen Erluo17,Adelberg David17,Shih Chie-Schin17,Shah Sukrut17,Bhagia Pooja17,Wainberg Zev A.18

Affiliation:

1. Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California

2. Yale Cancer Center, Smilow Cancer Hospital, New Haven, Connecticut

3. National Cancer Center Hospital East, Kashiwa, Japan

4. Vall d’Hebron University Hospital and Institute of Oncology, Baselga Oncological Institute–Quiron, University of Vic–Central University of Catalonia, Barcelona, Spain

5. Aichi Cancer Center Hospital, Nagoya, Japan

6. University Hospital Leuven and KU Leuven, Leuven, Belgium

7. Seoul National University College of Medicine, Seoul, Republic of Korea

8. University of Study of Campania Luigi Vanvitelli, Naples, Italy

9. The Oncology Centre, Durban, South Africa

10. National Cheng Kung University Hospital, Taiwan, People’s Republic of China

11. Royal Marsden Hospital, Sutton, Surrey, United Kingdom

12. North Estonia Medical Center Foundation, Tallinn, Estonia

13. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

14. Cerrahpaşa Medical Faculty, Cerrahpaşa School of Medicine, Istanbul University–Cerrahpaşa, Istanbul, Turkey

15. Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois

16. Mayo Clinic, Rochester, Minnesota

17. Merck Sharp & Dohme, a subsidiary of Merck & Co, Kenilworth, New Jersey

18. David Geffen School of Medicine, University of California, Los Angeles

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3